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Abstract
Plasmodiummalariae is widely distributed across the tropics, causing symptomatic malaria
in humans with a 72-hour fever periodicity, and may present after latency periods lasting up
to many decades. Delayed occurrence of symptoms is observed in humans using chemo-
prophylaxis, or patients having received therapies targeting P. falciparum intraerythrocytic
asexual stages, but few investigators have addressed the biological basis of the ability of P.
malariae to persist in the human host. To investigate these interesting features of P.malar-
iae epidemiology, we assembled, here, an extensive case series of P.malariaemalaria
patients presenting in non-endemic China, Sweden, and the UK who returned from travel in
endemic countries, mainly in Africa. Out of 378 evaluable P.malariae cases, 100 (26.2%)
reported using at least partial chemoprophylaxis, resembling the pattern seen with the
relapsing parasites P. ovale spp. and P. vivax. In contrast, for only 7.5% of imported UK
cases of non-relapsing P. falciparum was any chemoprophylaxis use reported. Genotyping
of parasites from six patients reporting use of atovaquone-proguanil chemoprophylaxis
did not reveal mutations at codon 268 of the cytb locus of the P.malariaemitochondrial
genome. While travellers with P.malariaemalaria are significantly more likely to report pro-
phylaxis use during endemic country travel than are those with P. falciparum infections, ato-
vaquone-proguanil prophylaxis breakthrough was not associated with pmcytbmutations.
These preliminary studies, together with consistent observations of the remarkable longev-
ity of P.malariae, lead us to propose re-examination of the dogma that this species is not a
relapsing parasite. Further studies are needed to investigate our favoured hypothesis,
namely that P.malariae can initiate a latent hypnozoite developmental programme in the
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human hepatocyte: if validated this will explain the consistent observations of remarkable
longevity of parasitism, even in the presence of antimalarial prophylaxis or treatment.
Author Summary
Plasmodium malariae is a widely distributed parasite infecting humans across the tropics,
and causing symptomatic malaria with a 72-hour fever periodicity. It is rarely studied.
This parasite has the notable ability to recur after many decades of apparent absence. Fur-
ther, people who have received drug treatment for other malaria infections, or to protect
themselves when travelling, sometimes develop malaria illness due to P.malariae resur-
gence months or years later. We set out to understand the ability of this largely ignored
parasite to persist in the human host. To do this we studied 359 P.malariaemalaria
patients in non-endemic China, Sweden, and the UK following endemic country travel,
mainly in Africa. These patients were much more likely to report protective use of malaria
drugs while travelling than were patients with P. falciparum infection. We tested for drug
resistance, but did not find any evidence that this played a part in parasite survival in these
travelers. We propose that P.malariaemay have a relapsing form in the liver, which per-
mits emergence of parasites into the blood months, years or decades after initial infection
from a mosquito bite.
Introduction
Human malaria is caused by six species of protozoan parasite: Plasmodium falciparum, P.
knowlesi, P.malariae, P. ovale curtisi, P. ovale wallikeri and P. vivax [1]. According to the
World Malaria Report 2014 [2], it is estimated that 198 million cases (uncertainty interval,
124–283 million) and 584 000 malaria deaths (uncertainty interval, 367 000–755 000) occurred
in 2014. Between 1994 and 2014, imported malaria was diagnosed in 38,198 travellers return-
ing to the United Kingdom [3,4]. The least common parasite species reported to the PHE
Malaria Reference Laboratory (MRL) during this period were P. knowlesi (1 case), and P.
malariae, responsible for 688 cases, 1.8% of the total overall, although in both 2013 and 2014 P.
malariae infections accounted for 2.6% of all imported malaria [3,4]. Little attention has been
paid to the latter species, and no particular chemoprophylaxis recommendations have been
developed for P.malariae, the general assumption being that infection with this species will be
prevented by any prescribed regimen that is effective against the more common P. falciparum
or P. vivax. Despite being widely distributed and present in all malaria endemic zones, only a
single case of P.malariae infection, in Costa Rica, is mentioned in the most recent World
Malaria Report [2].
The existing literature presents a conflicting picture of the drug responses of P.malariae.
Whereas an acceptable level of efficacy of most antimalarial drugs against P.malariae has been
reported in both field and clinic [5–7], recent data from Ghana and Uganda suggest that sub-
microscopic persistence of P.malariae infections after ACT treatment is not uncommon [8,9].
Further, there are sporadic case reports of recrudescent P.malariae parasitaemia in travellers
treated weeks or months prior for imported P. falciparummalaria [10,11], and renowned
instances of symptomatic P.malariaemalaria in individuals with no reported exposure to
infected Anophelesmosquitoes for several decades [12–14]. These observations are difficult to
explain if, as current dogma would suggest, P.malariae does not have a latent liver-stage
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hypnozoite analogous to that well-described for P. vivax and the monkey parasite P. cynomolgi
[15–16].
Among the more effective regimens for chemoprophylaxis in travellers, atovaquone as a
fixed dose combination with proguanil (AP) is particularly recommended in areas where P. fal-
ciparum is prevalent [17]. Although AP is also considered effective in both treatment and che-
moprophylaxis for the erythrocytic stages of P. vivax, P. ovale spp., and P.malariae [18,19], we
have recently shown that the two parasite species that cause ovale malaria, P. ovale curtisi and
P. ovale wallikeri, can occur despite patients reporting good adherence to AP chemoprophy-
laxis during endemic country travel [20]. Recrudescence of P. falciparum three or more weeks
after treatment does occur in a small proportion of AP-treated acute malaria patients [21–23].
Sequencing of the mitochondrial pfcytb locus of these recrudescent parasites has confirmed
that a single nucleotide polymorphism at codon 268 (Tyr to Asn, Ser or Cys) is associated with
treatment failure in vivo [21–23]. Despite these documented therapeutic failures, there are only
two cases of fully compliant AP chemoprophylaxis breakthrough of P. falciparum infection
documented in the literature, and this regimen has an estimated prophylactic efficacy against
falciparum malaria of greater than 99.9% [24]. Although AP may offer some protection against
P. vivax liver stages [19], one report describes a P. vivax-infected patient who experienced both
chemoprophylaxis breakthrough and treatment failure with AP, the relapse occurring five
months after the initial episode in the absence of pvcytbmutations [25]. Curiously, despite the
apparent lack of hypnozoites in this species, there are also reports of P.malariae surviving
treatment and chemoprophylaxis with a number of regimens including AP [11, 24, 26]. How-
ever, cytbmutations have not previously been evaluated in P.malariae, so it is unclear whether
this phenomenon represents an acquired resistance mechanism, or an intrinsic biological char-
acteristic of this parasite.
In this study, estimates of the latency period of imported P.malariae infections were derived
from data compiled by specialist centres in China and Sweden and from the UKMRL database.
Cases of P.malariae infection in travelers reporting use of AP for chemoprophylaxis, and for
whom frozen blood samples were available for DNA analysis, were identified in the UKMRL
database between 2007 and 2010, and sequences at codon 268 of pmcytb elucidated in each of
these putative breakthrough infections. Our findings are discussed with reference to published
examples of long-term persistence of infections with this parasite species, and propose recon-
sideration of the possibility that latent liver-stage hypnozoites do occur in P.malariae.
Methods
Study population
Anonymised clinical and epidemiological data on cases of P.malariaemalaria reported to the
PHEMRL, London, from 1991 to 2010, cases of P.malariaemalaria seen at the Karolinska
University Hospital, Stockholm, Sweden, between 1997 and 2013 and cases of P.malariae
infection diagnosed in Jiangsu Province and reported to the Institute for Parasitic Diseases,
Wuxi, China, were available. For a subset of the London series, DNA samples were provided
for pmcytb gene sequencing. All cases in each site were identified by expert microscopists work-
ing at Reference Laboratory standard. PCR confirmation was also carried out for all cases from
China, five of those from Sweden and all six UK cases subjected to pmcytb sequencing.
Sample identification
The sample set for pmcytb analysis was identified among entries in the database collected by
the PHE MRL at the London School of Hygiene and Tropical Medicine (LSHTM). Patients
were selected who satisfied all three of the following criteria:
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1. reported use of AP chemoprophylaxis whilst travelling abroad;
2. diagnosis of slide-positive P.malariae infection confirmed by the MRL;
3. availability of a blood sample or purified DNA in the MRL sample archive.
Sixteen samples were identified which fitted criteria 1 and 2, for six of which a blood sample
was available. Drug resistance testing was performed under the surveillance remit of the MRL.
All patient identifiers have been removed.
DNA extraction and PCR for detection of codon 268 mutations in
cytochrome b
Parasite DNA was extracted from patient blood samples using the QIAamp DNA Blood Mini
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. Primers were
designed specifically for this study, based on P.malariae cytochrome b (pmcytb; NCBI acces-
sion number: AB354570.1). Primer sequences were as follows:
Pmcytb1 5’-TGTTTTACCATGGGGACAAAT-3’
Pmcytb2 5’-CACCAATACAAATTGTTCCAGA-3’
Pmcytb3 5’-TGTGGTAATTGACATCCAATCC-3’
Sequencing templates were amplified using a hemi-nested protocol which generated a
635bp nest 1 product (Pmcytb1 + Pmcytb3) and a 253bp nest 2 product (Pmcytb2 + Pmcytb3)
encompassing codons 255 to 337 of the pmcytb locus. The presence of mutations at codon 268
was investigated by direct sequencing of PCR amplicons.
For the primary amplification reaction, a 25μL mix that contained 1X KCl PCR buffer (Bio-
line, UK), 15mMMgCl2, 0.2mM deoxyribonucleotide triphosphates (Bioline, UK), 0.25nM
each of primers Pmcytb1 and Pmcytb3 (Eurofins, Germany), 0.2μL Taq polymerase (Bioline,
UK), and 2μL of extracted parasite DNA was initially heated at 92°C for 3 minutes, then cycled
at 92°C for 30 seconds, 55°C for 50 seconds, and 68°C for 90 seconds for 35 cycles, with a final
extension at 68°C for 5 minutes. 1μL of PCR product was then added to 19.3μL of nuclease-
free water, 0.5μL Pmcytb2 and Pmcytb3 each, and identical volumes of dNTPs, Taq polymer-
ase, and PCR buffer as described in the first amplification reaction to make a total mix of 25μL.
30 further cycles of PCR were applied, as above. PCR products were sequenced using the ABI
Prism BigDye Terminator kit (Applied Biosystems, Warrington, UK) according to the manu-
facturer’s instructions, primed by Pmcytb2 and Pmcytb3. Sequencing data was visualized and
analyzed using Chromas software (Technelysium, Australia).
Statistical analysis
Continuous data (number of days delay to appearance of symptoms) were not normally dis-
tributed, and comparisons between categories were therefore performed using the non-
parametric Wilcoxon’s rank-sum test. Categorical data were analysed in 2 x 2 tables to provide
odds ratios (OR), and statistical significance was estimated from the χ2 distribution. Statistical
analysis was performed in STATA 12 (StataCorp, USA). All data were de-linked from personal
identifiers.
Results
Analysis of latency in imported P.malariae cases from three countries
Two parameter, time elapsed from arrival in a non-endemic setting to symptomatic presenta-
tion for diagnosis, and the delay to onset of symptoms, were explored among 638 cases of P.
malariae infection. These comprised:
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- 6 travellers diagnosed as imported cases of P.malariaemalaria in various hospitals, and
confirmed by the Jiangsu Institute of Parasitic Diseases (JIPD), in Jiangsu province, China
between 2012 and 2013
- 21 cases of imported P.malariaemalaria identified at Karolinska University Hospital,
Stockholm, Sweden, between 1997 and 2013
- 611 cases of imported P.malariaemalaria presenting to UK hospitals between 1991 and
2010 and reported to the UKMRL.
For many individuals, insufficient data were available to estimate either or both parameters
of interest. Table 1 presents a summary of evaluable data from all three sources.
Reported use of chemoprophylaxis prior to diagnosis with P.malariaemalaria was tested as
a likely modulator of delay to onset of symptoms. Patients reporting no chemoprophylaxis
while travelling in endemic countries experienced a geometric mean delay of 20.0 days (95% CI
16.5–24.2; N = 146) between arrival in the non-endemic country and onset of symptoms, com-
pared to a geometric mean delay of 36.1 days (95% CI 28.8–45.3; N = 72) in those reporting
any chemoprophylaxis use (Wilcoxon’s ranksum test z = -4.106; P< 0.001). Fig 1 presents the
distribution of delay to onset of symptoms in these two groups of patients.
Among 77 patients reporting use of a particular chemoprophylaxis regimen, and for whom
date of onset of symptoms was also available, the three most frequently used drugs were meflo-
quine (N = 29), chloroquine (with or without proguanil; N = 19) and AP (N = 17). Of these,
mefloquine generated the greatest increase in geometric mean delay to symptoms (53.9 days;
95% CI 38.3–75.7), followed by AP (34.3 days; 95% CI 20.3–58.1). In total, 26.5% of the 378 P.
malariaemalaria cases for which data were available reported chemoprophylaxis use, an esti-
mate very similar to that for 4,133 cases of the relapsing parasite P. vivax (Table 2; P = 0.2315).
In contrast, only 7.7% of a data sample of 2, 814 P. falciparummalaria cases entered in the UK
MRL database between 1991 and 2010 reported chemoprophylaxis use (P< 0.0001) [20].
Role of pmcytbmutations in AP chemoprophylaxis breakthrough
DNA sequence data were successfully obtained for isolates from six patients with recorded use
of AP chemoprophylaxis prior to onset of malaria. These data were aligned with published P.
malariae cytochrome b sequence (NCBI accession number: AB354570.1) isolated from a
human case (Fig 2). No mutations were present at position 268 in any patient isolate. One
other non-synonymous difference from the pmcytb reference sequence was identified. Patient
3, a 20 year old Caucasian British male with a history of recent travel to Uganda, exhibited a
single Phe306Leu mutation, previously described from a P.malariae infection in one wild
chimpanzee, Pan troglodytes verus, from Côte d’Ivoire (Genbank Accession: ADP68607.1)
[27].
Discussion
This study of imported cases of P.malariaemalaria evaluated the time elapsed between post-
travel arrival in China, Sweden or the UK and clinical presentation and diagnosis of malaria as
a proxy measure of latency. A significant relationship between use of chemoprophylaxis and
delayed presentation was observed, although some late presentations with P.malariaemalaria
were also seen in patients with no history of chemoprophylaxis use during travel. Out of 359
evaluable P.malariae cases in this study, 26.5% reported using at least partial chemoprophy-
laxis, closely resembling the patterns seen with the relapsing parasites P. ovale curtisi, P. ovale
wallikeri and P. vivax, whereas for 2,814 imported cases infected with the non-relapsing para-
site P. falciparum, only 7.5% reported chemoprophylaxis use (Table 2) [20]. No evidence was
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found that mutations in the parasite locus pmcytb were the cause of breakthrough in 6 travelers
who reported using atovaquone-proguanil chemoprophylaxis while at risk of malaria infection.
This suggests an intrinsic biological property of this parasite species permits evasion of
Table 1. Summary of delay from arrival in non-endemic region to onset of symptoms and to date of diagnosis for 326 cases of imported P.malariae
infection.
Patient
origin
Total
cases
Travel destinations
(frequency)
Median delay from arrival to onset of
symptoms (IQR) [range]
Median delay from arrival to diagnosis
(IQR) [range]
China 6 Equatorial Guinea (3) 20 days 27.5 days
Angola (1) (5–37) (13–37)
Liberia (1) [2–126] [9–127]
Nigeria (1) N = 6 N = 6
Sweden 21 Uganda (5) 19 days 31 days
The Gambia (4) (13–47) (20.5–59.5)
Kenya (3) [0–70] [3–84]
Ghana (2) N = 20 N = 20
5 other African origins
United
Kingdom
611 Nigeria (150) 24 days 31 days
Uganda (64) (9–50) (16–66)
Ghana (61) [-5–1123] [0–1758]
Kenya (46) N = 248 N = 333*
Congo (16)
Cameroon (15)
Malawi (13)
Sierra Leone (13)
Gambia (12)
Tanzania (12)
Ivory Coast (8)
Mozambique (7)
Zambia (4)
Zimbabwe (4)
Sudan (3)
Liberia (2)
Madagascar (2)
Senegal (2)
South Africa (2)
Togo (2)
10 single African origins;
55 unspeciﬁed “Africa”;
Non-African origin:
Brunei (1)
French Guiana (1)
Guyana (1)
Malaysia (1)
New Guinea (1)
Pakistan (1)
Yemen (1)
* Date of diagnosis was more reliably collected than date of onset of symptoms in the UK dataset.
doi:10.1371/journal.pntd.0004068.t001
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chemoprophylaxis in a small number of travelers. Our favoured explanation is that the human
malaria parasite P.malariae is also a relapsing parasite, with the ability to form latent hypno-
zoite stages in the host liver, and that these can initiate new intra-erythrocytic asexual replica-
tion months or years after the initial infective mosquito bite. However, we cannot rule out the
possibility that P.malariaemay have a hitherto undescribed persistence strategy, such as the
generation of metabolically arrested blood-stage forms, or an alternative extra-erythrocytic
cycle in a tissue other than liver, which permits evasion of chemoprophylaxis.
We found evidence that the delay from leaving the endemic area to onset of symptoms in
imported malaria cases caused by P.malariae has a wide range, from 0 to 1123 days, and that
chemoprophylaxis use makes it significantly more likely that this delay would be extended. In
fact, over a quarter of our cases reported chemoprophylaxis use, such that in the UK dataset a
Fig 1. Delay to onset of symptoms in 273 P.malariae patients presenting with importedmalaria in China, Sweden and the UK. Blue markers denote
those reporting no chemoprohylaxis use. One outlier from the UK dataset (delay to onset: 1123 days) was excluded.
doi:10.1371/journal.pntd.0004068.g001
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clinical case of P.malariaemalaria is 4 times more likely to occur in a traveller who used che-
moprophylaxis than is a P. falciparum–infected case (Table 2; P< 0.0001), but is no more or
less likely to do so than cases of vivax malaria. Thus the epidemiology of imported P.malariae
infections mirrors that of the relapsing parasite P. vivax, but is significantly different from that
of the non-relapsing parasite P. falciparum. These data are consistent with the findings of
Schwartz et al. [26] who, in a series of 2,822 imported malaria cases from the USA in the 1990s
(when chloroquine was typically deployed) found that 13.6% of P. falciparum cases reported
compliant use of prophylaxis, compared to 31.5%, 42.9% and 29.0% for P.malariae, P. ovale
spp. and P. vivax, respectively.
In our series of 6 patients with P.malariaemalaria who reported atovaquone-proguanil che-
moprophylaxis use, the absence of pmcytbmutations at codon 268 provides some evidence
that this is an intrinsic property of the parasite rather than an acquired genetic resistance
mechanism. Conversely, these observations may reflect drug malabsorption (which we were
not able to investigate), or mutations at other positions of pmcytb, as were reported in experi-
mentally drug-pressured atovaquone-resistant P. yoelii parasite lines, where codons other than
Table 2. Proportion of importedmalaria cases reporting chemoprophylaxis use, by species.
Px not used Px used Total OR P. malariae vs other; (95% CI) P
P. malariae (this study) 278 100 378 - -
73.5% 26.5%
P. falciparum * 2,597 217 2,814 4.30; (3.26–5.66) < 0.0001
92.3% 7.7%
P. ovale spp.* 667 378 1,045 0.634; (0.48–0.83) 0.0006
63.8% 36.2%
P. vivax* 3,153 980 4,133 1.16; (0.901–1.48) 0.232
76.3% 23.7%
Total 6,695 1,675 8,370 - -
80.0% 20.0%
Px–chemoprophylaxis;
Px used–chemoprophylaxis use reported, any regimen
OR–odds ratio for not using chemoprophylaxis compared to P. malariae data
* UK MRL data 1991–2010 [20].
doi:10.1371/journal.pntd.0004068.t002
Fig 2. Gene sequencing results of second amplification products with previously published P.malariae cytochrome b sequence as reference.
Y268 is clearly indicated by shading, showing the wild-type Y268 residue is present in all isolates. One residue differing from the reference sequence in
patient 3 is highlighted.
doi:10.1371/journal.pntd.0004068.g002
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position 268 of the pycytb locus were found to be substituted with novel amino acids [28]. Fur-
ther sequencing could explore this latter possibility.
An unexpected finding among our sample set was an isolate from Uganda that encoded an
amino acid change in the pmcytb gene only previously reported from a wild-caught chimpan-
zee in Sierra Leone. This provides some support for the hypothesis that African malaria para-
sites of all species shuttle between great ape and human hosts [29], as recent data for both P.
falciparum and P. vivax suggest [30,31]. This form of pmcytb could be of human origin, existing
as a minor variant across P.malariae populations among Homo sapiens in Africa, which hap-
pened to be transferred to Pan troglodytes verus in Cote d’Ivoire. Alternatively, there may be
genetically diverse P.malariae across the wild ape populations of central and western Africa,
which provide a reservoir of new genetic variants for human-focussed transmission cycles [27].
Further sampling and sequencing in both hosts is needed to explore these possibilities.
We find support in our data for the notion that P.malariae is a truly relapsing parasite spe-
cies, and has a quiescent liver-stage form analogous to the well-described hypnozoites of P.
vivax and the simian parasite P. cynomolgi. This hypothesis could be tested experimentally, as
Dembele et al [32] have recently been able to infect hepatocytes ofMacaca fascicularis with
sporozoites of Plasmodium cynomolgi and directly demonstrate persistence and later activation
of hypnozoites. Infection of human hepatocytes with P.malariae sporozoites should be techni-
cally feasible. Our conclusion is in contradiction to the findings of Ciuca et al. [5], who admin-
istered a Romanian strain of P.malariae to three volunteers by sporozoite inoculation together
with a single dose of 50mg pyrimethamine. Over 8 to 18 months’ follow-up, none of the volun-
teers developed a blood-stage P.malariae infection. Similarly, six volunteers with experimen-
tally-induced blood-stage parasitaemia with the same Romanian P.malariae isolate were
successfully treated with various antimalarial regimens. No relapses occurred in any of these
volunteers over 15 months’ follow-up. These authors conclude the following: “Ces constata-
tions imposent la conclusion logique que P.malariae n’aurait qu’une phase tissulaire prééry-
throcytaires unique<< la schizogonie exoérythrocytaire primaire>>.” (There is only a single
hepatic shizogony cycle in each infection.) [5] Coatneyi et al comment on these findings of
Ciuca et al thus: “In this connection, we also have observed no relapse activity after adequate
blood schizonticidal therapy in our volunteers exposed to infection with a Nigerian strain of P.
malariae. It seems safe to say that, in this respect, P.malariae resembles P. falciparummore
than it does the human tertian malarias which do relapse.” [33]
There are several tentative explanations that might help us to reconcile our findings with
the earlier evidence from experimentally induced infections that P.malariae does not relapse.
Firstly, the initiation of a secondary hepatic cycle may be a rare event in P.malariae and thus a
handful of volunteers may not have been a large enough sample to detect relapse events. Sec-
ondly, follow-up of less than 2 years may have missed late events in these individuals, as P.
malariae is without doubt the human parasite with the greatest within-host longevity. Thirdly,
the putative hypnozoite stage of P.malariaemay not be identical to that of P. vivax in its mech-
anism of arrest; if metabolism halts at a later stage of intra-hepatocytic development, these
forms may not be completely insensitive to full therapeutic doses of pyrimethamine or other
antimalarials (although would appear able to escape low-dose chemo-prophylaxis). Finally,
some “strains” of P.malariaemay have lost the ability to form hypnozoite-like stages in the
host liver, and thus the single Romanian parasite line of Ciuca et al. [5], and the single Nigerian
line described by Coatneyi et al. [33] could have been non-relapsing types. Further studies are
required to tease apart these various alternatives, and the recent development of appropriate
humanised mouse models for liver-stage studies offers an exciting new strategy for pursuit of
this question [34].
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Conclusions
Analysis of delay to onset of symptoms in a large series of imported quartan malaria cases in
three non-endemic countries, and elucidation of the pmcytb sequences of P.malariae isolates
from a subset of users of atovaquone-proguanil chemoprophylaxis, lead us to conclude that P.
malariaemay be able to form hypnozites, or an analogous liver-stage form. As Garnham has
observed: “. . . true long term relapses of sporozoite induced infections seem more likely to be
due to a secondary exoerythrocytic cycle in the liver, known to occur in other species, than to a
persistent low-grade parasitaemia.” (P. 269) [35]. Whereas Garnham subsequently changed his
view [36], our data and the work of others [11; references therein] support re-evaluation of the
possibility that P.malariae is a relapsing parasite.
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